Results 31 to 40 of about 867,189 (360)

Cancer Immunotherapy Using Checkpoint Blockade

Science, 2018
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers.
A. Ribas, J. Wolchok
semanticscholar   +1 more source

Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms [PDF]

, 2002
Background: Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur in the treatment of hymenoptera sting allergy. The objective of the present study was to examine the characteristics of allergic reactions during Rush-SIT in a ...
Mingomataj, Ervin, Fischer, Axel, Qirko, Etleva, Peiser, Christian, Groneberg, Jan David Alexander, Priftanji, Alfred, Dinh, Q. Thai   +6 more
core   +1 more source

Oncolytic Virus Immunotherapy

, 2021
Oncolytic viruses (OVs) were originally developed as direct cytotoxic agents but have been increasingly recognised as a form of immunotherapy [...
Carolina S. Ilkow, Antonio Marchini, Alan Melcher   +2 more
core   +1 more source

Modulation of Endosome Function, Vesicle Trafficking and Autophagy by Human Herpesviruses

Cells, 2021
Human herpesviruses are a ubiquitous family of viruses that infect individuals of all ages and are present at a high prevalence worldwide. Herpesviruses are responsible for a broad spectrum of diseases, ranging from skin and mucosal lesions to blindness ...
Eduardo I. Tognarelli, Antonia Reyes, Nicolás Corrales, Leandro J. Carreño, Susan M. Bueno, Alexis M. Kalergis, Pablo A. González   +6 more
doaj   +1 more source

Immunotherapy [PDF]

OncoImmunology, 2012
The Janus-faced roles of macrophages in cancer imply both tumor-suppressive and -stimulating actions of these innate immune cells. Whereas the balance is toward tumor promotion in most epithelial cancers, we have recently shown that osteosarcoma metastasis seems to be inhibited by macrophages. Here we discuss the possible mechanism of this observation.
Cleton-Jansen, A.M., Buddingh, E.P., Lankester, A.C.   +2 more
openaire   +3 more sources

Clinical effectiveness of hymenoptera venom immunotherapy [PDF]

, 2013
Treatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors. Our aim was to evaluate the association of baseline serum tryptase concentration (BTC) and of other parameters with the frequency of VIT failure during ...
Scheipl, Fabian, Darsow, Ulf, Reider, Norbert, Bonifazi, Floriano, Aberer, Werner, Schmid-Grendelmeier, Peter, Ruëff, Franziska, Treudler, Regina, Biló, Maria Beatrice, Sturm, Gunter Johannes, Küchenhoff, Helmut, Severino, Maurizio, Wüthrich, Brunello, Seitz, Michael J., Quercia, Oliviero, Bodzenta-Lukaszyk, Anna, Lang, Roland, Haeberli, Gabrielle, Campi, Paolo, Hawranek, Thomas, Müller, Ulrich, Przybilla, Bernhard   +21 more
core   +1 more source

Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo

Nature Communications, 2022
Plasma B cells (PC) are a potential source for protein replacement as they could be engineered to secrete protein other than antibody. Here the authors engineer B cells to express exogenous proteins and demonstrate that these cells can persist long term ...
Rene Yu-Hong Cheng, King L. Hung, Tingting Zhang, Claire M. Stoffers, Andee R. Ott, Emmaline R. Suchland, Nathan D. Camp, Iram F. Khan, Swati Singh, Ying-Jen Yang, David J. Rawlings, Richard G. James   +11 more
doaj   +1 more source

Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8+ T cells eradicates peritoneal metastases in mouse models

OncoImmunology, 2023
Previous studies have shown that local delivery of tumor antigen-specific CD8+ T lymphocytes engineered to transiently express single-chain IL-12 mRNA is highly efficacious.
Claudia Augusta Di Trani, Assunta Cirella, Leire Arrizabalaga, Ángela Bella, Myriam Fernandez-Sendin, Joan Salvador Russo-Cabrera, Celia Gomar, Irene Olivera, Elizabeth Bolaños, José González-Gomariz, Maite Álvarez, Iñaki Etxeberria, Belen Palencia, Álvaro Teijeira, Ignacio Melero, Pedro Berraondo, Fernando Aranda   +16 more
doaj   +1 more source

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Journal for ImmunoTherapy of Cancer, 2019
.
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz Jr, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau   +40 more
doaj   +1 more source

The blockade of immune checkpoints in cancer immunotherapy

Nature Reviews. Cancer, 2012
Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self ...
D. Pardoll
semanticscholar   +1 more source